Moderna and Merck report mRNA cancer vaccine cuts melanoma recurrence in late-stage trial

Moderna’s new mRNA vaccine, Intismeran, has shown encouraging results in late‑stage trials, markedly lowering both recurrence and metastatic spread of melanoma. The study, conducted across multiple oncology centers, evaluated the vaccine’s efficacy as an adjuvant therapy in patients who had completed standard surgical and chemotherapeutic regimens.

In the trial, patients receiving Intismeran experienced a significant reduction in tumor recurrence compared with those given a placebo, while imaging data indicated fewer cases of distant metastasis. The vaccine’s design targets key melanoma antigens, prompting a robust immune response that appears to enhance the body’s ability to eliminate residual cancer cells. These findings suggest that mRNA technology can be effectively harnessed not only for prevention but also for post‑treatment cancer control.

If subsequent confirmatory studies corroborate these outcomes, Intismeran could become a pivotal addition to melanoma management protocols, offering a novel therapeutic avenue that improves long‑term survival and quality of life for patients facing this aggressive skin cancer.